Skip to Content

Brokerages have assigned a consensus rating of “Buy” to Fusion Pharmaceuticals Inc. (NASDAQ:FUSN).

Brokerages have assigned a consensus rating of “Buy” to Fusion Pharmaceuticals Inc. (NASDAQ:FUSN).

According to Bloomberg, the seven rating agencies presently keeping an eye on Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) have collectively provided the company with a recommendation to “buy” their stock. This recommendation is the average of the individual agencies’ recommendations. The recommendation to buy the stock has been backed by the opinions of seven different financial analysts. The price target of $11.67 per share has been determined to be the consensus price target projection for the next 12 months among market experts who have covered the stock in the preceding year.

FUSN has received feedback on various topics from various research firms. On November 30th, SVB Leerink made a report on Fusion Pharmaceuticals available to the public. They have assigned the company the rating of “outperform,” and their price objective is $6.00. B. Riley reaffirmed a “buy” rating on shares of Fusion Pharmaceuticals and outlined a price objective of $10.00 for the company in a research report dated Thursday, December 1st. The report was published on the company’s website.

When trading started on Thursday, the price of a share of Fusion Pharmaceuticals was $3.83 per share. There is a debt-to-equity ratio of 0.19, a current ratio of 16.09, and a quick ratio that is identical to the current ratio. All of these figures are presented about one another. With a price-to-earnings ratio of 2.07 and a beta value of 0.97, the company has a market capitalization of $171.44 million due to these two metrics. The stock currently trades at $2.79, above the 50-day and the 200-day moving averages, each sitting at $2.60, respectively. Over the previous year, the price of Fusion Pharmaceuticals ranged from a low of $1.98 to a high of $8.73 at various points.

On November 8th, the most recent quarterly earnings report for Fusion Pharmaceuticals, traded on the NASDAQ under the symbol FUSN, was made public. The company reported $0.55 per share earnings for the quarter, which was $0.03 less than the average prediction of $0.52 per share for the quarter. The revenue for the quarter came in at $0.17 million, a significant drop from the $0.50 million that experts in the industry had anticipated the quarter would bring in. The return on equity for Fusion Pharmaceuticals was negative by 38.72%, and the net margin for the company was negative by 4,189.61%. Sell-side analysts have anticipated that Fusion Pharmaceuticals will finish the current financial year with earnings of -2.03 cents per share.

During recent years, significant shareholders in the company have been active in taking action to bring about change. Through the second quarter, Millennium Management LLC provided Fusion Pharmaceuticals with a financial contribution of $29,000. Prudential Financial, Inc. made a financial investment in the amount of $44,000 in Fusion Pharmaceuticals during the third quarter of 2018. Renaissance Technologies LLC made a new investment in the amount of $51,000 in Fusion Pharmaceuticals during the third quarter of the fiscal year. UBS Oconnor LLC spent $52,000 during the third quarter to acquire a new holding in Fusion Pharmaceuticals. This investment was made in the company’s stock. Citadel Advisors LLC invested $86,000 in Fusion Pharmaceuticals during the third quarter, which brings us to our final and most important point. Institutional and hedge fund investors hold ownership positions equivalent to 59.39% of the total number of shares issued by the company.

Radiopharmaceuticals are one type of precision medicine currently being developed by Fusion Pharmaceuticals, Inc., an oncology company currently in the clinical stage of product development. The company created the Targeted Alpha Therapies platform by attaching alpha particle-emitting isotopes to various targeted molecules using the patented Fast-Clear linker technology. This allowed the platform to treat a wider range of conditions. We can target tumors with pinpoint accuracy and deliver alpha particle payloads.


Leave a comment

Your email address will not be published. Required fields are marked *